S. Dalva-Aydemir Et Al. , "Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin," CLINICAL CANCER RESEARCH , vol.21, no.5, pp.1161-1171, 2015
Dalva-Aydemir, S. Et Al. 2015. Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin. CLINICAL CANCER RESEARCH , vol.21, no.5 , 1161-1171.
Dalva-Aydemir, S., Bajpai, R., Martinez, M., Adekola, K. U. A., Kandela, I., Wei, C., ... Singhal, S.(2015). Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin. CLINICAL CANCER RESEARCH , vol.21, no.5, 1161-1171.
Dalva-Aydemir, SEVİM Et Al. "Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin," CLINICAL CANCER RESEARCH , vol.21, no.5, 1161-1171, 2015
Dalva-Aydemir, SEVİM D. Et Al. "Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin." CLINICAL CANCER RESEARCH , vol.21, no.5, pp.1161-1171, 2015
Dalva-Aydemir, S. Et Al. (2015) . "Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin." CLINICAL CANCER RESEARCH , vol.21, no.5, pp.1161-1171.
@article{article, author={SEVİM DALVA AYDEMİR Et Al. }, title={Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin}, journal={CLINICAL CANCER RESEARCH}, year=2015, pages={1161-1171} }